{"id":"NCT02418845","sponsor":"Symbiomix Therapeutics","briefTitle":"A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis","officialTitle":"A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-28","primaryCompletion":"2015-10-05","completion":"2015-12-05","firstPosted":"2015-04-16","resultsPosted":"2021-04-13","lastUpdate":"2021-10-15"},"enrollment":189,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Vaginosis"],"interventions":[{"type":"DRUG","name":"SYM-1219","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SYM-1219","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this clinical trial is to test the safety and efficacy of the oral investigational new drug, SYM-1219 for the treatment of bacterial vaginosis.","primaryOutcome":{"measure":"Clinical Outcome Responder Rate","timeFrame":"Study Days 21-30 (End of Study (EOS))","effectByArm":[{"arm":"SYM-1219","deltaMin":57,"sd":null},{"arm":"Placebo","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":125},"commonTop":["Vulvovaginal mycotic infection","Vulvovaginal candidiasis","Headache","Nausea","Diarrhoea"]}}